Characteristics | Value | Characteristics | Value |
---|---|---|---|
No. of patients | 147 | ECOG PS | Â |
Age at diagnosis (years) |  | 0–1 | 112 (76.2%) |
 < 70 | 92 (62.6%) | 2 | 35 (23.8%) |
 ≥ 70 | 55 (37.4%) | GPS |  |
Gender | Â | 0 | 103 (70.1%) |
 Male | 71 (48.3%) | 1 | 24 (16.3%) |
 Female | 76 (51.7%) | 2 | 20 (13.6%) |
Primary site | Â | SII | Â |
 Upper lip | 17 (11.6%) | Median | 1138 |
 Lower lip | 130 (88.4%) | IQR | 686–1573 |
Grade | Â | PNI | Â |
 Well differentiate | 66 (44.9%) | Median | 73 |
 Moderate differentiate | 44 (29.9%) | IQR | 49–96 |
 Poor differentiate | 37 (25.2%) | PLR |  |
AJCC stage | Â | Median | 148 |
 I | 28 (19.0%) | IQR | 93–202 |
 II | 39 (26.5%) | ACCI |  |
 III | 52 (35.4%) | < 5 | 87 (59.2%) |
 IV | 28 (19.0%) | ≥ 5 | 60 (40.8%) |
Perineural invasion | Â | NLR | Â |
 No | 135 (91.8%) | Median | 2.42 |
 Yes | 12 (8.2%) | IQR | 1.34–3.29 |
Vascular invasion | Â | Hemoglobin (g/L) | Â |
 No | 127 (86.4%) | Median | 101 |
 Yes | 20 (13.6%) | IQR | 90–121 |
Surgical margin (mm) | Â | Multiple primary tumors | Â |
 < 5 | 23 (15.7%) | Yes | 11 (7.5%) |
 ≥ 5 | 124 (84.4%) | No | 136 (92.5%) |
ENE | Â | BMI (kg/m2) | Â |
 Negative | 129 (87.8%) | Median | 21.3 |
 Positive | 18 (12.2%) | IQR | 19.6–25.0 |
Adjuvant chemotherapy | Â | OS (months) | Â |
 No | 94 (63.9%) | Median | 72 |
 Yes | 53 (36.1%) | Range | 6–133 |
Adjuvant radiotherapy | Â | PFS (months) | Â |
 No | 63 (42.9%) | Median | 64 |
 Yes | 84 (57.1%) | Range | 4–132 |